Use of radioiodinated peptide Arg-Arg-Leu targeted to neovascularization as well as tumor cells in molecular tumor imaging

Chinese Journal of Cancer Research

Volumn 24, Issue 1, 2012, Pages 52-59

  Lu, Xia ^a,b,c   Yan, Ping ^a   Wang, Rong Fu ^a   Liu, Meng ^a   Yu, Ming Ming ^d   Zhang, Chun Li ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b Beijing Aerospace General Hospital   (China)

^c BEIJING NORMAL UNIVERSITY   (China)

^d YANGZHOU UNIVERSITY   (China)

Author keywords

Iodine 131; Molecular tumor imaging; Peptide Arg Arg Leu (tRRL); Uptake ability

Indexed keywords

ARGINYLARGINYLLEUCINE I 131; IODINE 131; TRIPEPTIDE; TYROSINE; TYROSYLCYSTEINYLGLYCYLGLYCYLARGINYLARGINYLLEUCYLGLYCYLGLYCYLCYSTEINE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DISTRIBUTION; DRUG UPTAKE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOLECULAR IMAGING; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUCLEOTIDE MOTIF; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR XENOGRAFT;

EID: 84863670972     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-012-0052-8     Document Type: Article

References (28)

1. Glunde K, Pathak AP, Bhujwalla ZM. Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med 2007; 13:287-97. (Pubitemid 47017002)
2. Gupta PB, Mani S, Yang J, et al. The evolving portrait of cancer metastasis. Cold Spring Harb Symp Quant Biol 2005; 70:291-7. (Pubitemid 44124883)
3. Wagner HN Jr. Advancing a molecular theory of disease. J Nucl Med 2008; 49:15N-34N.
4. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29(6 Suppl 16):15-8.
5. Aiello LP. Keeping in touch with angiogenesis. Nat Med 2000; 6:379-81. (Pubitemid 30208150)
6. Rosen L. Antiangiogenic strategies and agents in clinical trials. Oncologist 2000; 5(Suppl 1):20-7. (Pubitemid 30225453)
7. Davis DW, McConkey DJ, Abbruzzese JL, et al. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003; 89:8-14. (Pubitemid 36897928)
8. Costouros NG, Diehn FE, Libutti SK, et al. Molecular imaging of tumor angiogenesis. J Cell Biochem Suppl 2002; 39:72-8. (Pubitemid 36176558)
9. Anderson H, Price P, Blomley M, et al. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001; 85:1085-93. (Pubitemid 33052303)
10. Padhani AR. Functional MRI for anticancer therapy assessment. Eur J Cancer 2002; 38:2116-27. (Pubitemid 35223249)
11. Miles KA. Functional computed tomography in oncology. Eur J Cancer 2002; 38:2079-84. (Pubitemid 35223245)
12. Heppeler A, Froidevaux S, Eberle AN, et al. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7:971-94.
13. Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45:189-200. (Pubitemid 32640394)
14. Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421-9.
15. Okarvi SM. Recent developments in 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nucl Med Commun 1999; 20:1093-112. (Pubitemid 30039331)
16. Weiner RE, Thakur ML. Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002; 57:749-63. (Pubitemid 35279166)
17. Foss CA, Mease RC, Fan H, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005; 11:4022-8. (Pubitemid 40791565)
18. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phase display peptide libraries. Nature 1996; 380:364-6. (Pubitemid 26097120)
19. Rajotte D, Arap W, Hagedorn M, et al. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102:430-7. (Pubitemid 28335203)
20. Brown CK, Modzelewski RA, Johnson CS, et al. A novel approach for the identification of unique tumor vasculature binding peptides using an E. coli peptide display library. Ann Surg Oncol 2000; 7:743-9.
21. Weller GE, Wong MK, Modzelewski RA, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res 2005; 65:533-9.
22. Henry DO, Chen SC, Wong MK, et al. Targeted molecular imaging of prostate cancer using tumor endothelium homing Arg-Arg-Leu peptides. J Clin Oncol 2006; 24:14582.
23. Yu MM, Wang RF, P Yan, et al. Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma. J Label Compd Radiopharm 2008; 51:374-8.
24. 123I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphy. Int J Cancer 2001; 91:789-96. (Pubitemid 32178646)
25. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-27. (Pubitemid 46202320)
26. Li S, Peck-Radosavljevic M, Kienast O, et al. Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy. Ann Oncol 2003; 14:1274-7. (Pubitemid 37039055)
27. Schaefer NG, Ma J, Huang P, et al. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 2010; 51:987-94.
28. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.